Cancer Genetics, Inc. (CGIX) Analysts See $-0.11 EPS

March 16, 2018 - By Richard Conner

 Cancer Genetics, Inc. (CGIX) Analysts See $ 0.11 EPS
Investors sentiment decreased to 0.57 in Q3 2017. Its down 0.60, from 1.17 in 2017Q2. It is negative, as 5 investors sold Cancer Genetics, Inc. shares while 9 reduced holdings. 4 funds opened positions while 4 raised stakes. 2.58 million shares or 6.28% less from 2.76 million shares in 2017Q2 were reported.
Wells Fargo & Mn reported 15,823 shares stake. Geode Mgmt Limited Co reported 87,279 shares. Perkins Cap Management has 2.28% invested in Cancer Genetics, Inc. (NASDAQ:CGIX) for 806,700 shares. Royal Comml Bank Of Canada accumulated 0% or 809 shares. Bancorp Of Montreal Can invested 0% in Cancer Genetics, Inc. (NASDAQ:CGIX). Tower Research Cap Ltd (Trc) reported 1,342 shares or 0% of all its holdings. Granahan Inv Mgmt Inc Ma holds 237,431 shares or 0.05% of its portfolio. Barclays Public Ltd Company holds 0% in Cancer Genetics, Inc. (NASDAQ:CGIX) or 454 shares. Thompson Davis & Incorporated invested in 46,975 shares or 0.22% of the stock. Two Sigma Limited Liability Corp holds 14,616 shares or 0% of its portfolio. Next Finance Gru has 0% invested in Cancer Genetics, Inc. (NASDAQ:CGIX). Bancorp Of America De holds 625 shares. Northern Corp holds 0% or 34,771 shares. Virtu Limited Liability Co owns 0% invested in Cancer Genetics, Inc. (NASDAQ:CGIX) for 18,600 shares. Diker Mngmt Lc reported 0.07% in Cancer Genetics, Inc. (NASDAQ:CGIX).

Since December 15, 2017, it had 1 insider purchase, and 0 sales for $24,339 activity.

Analysts expect Cancer Genetics, Inc. (NASDAQ:CGIX) to report $-0.11 EPS on March, 22.They anticipate $0.04 EPS change or 26.67 % from last quarter’s $-0.15 EPS. After having $-0.16 EPS previously, Cancer Genetics, Inc.’s analysts see -31.25 % EPS growth. The stock decreased 5.26% or $0.1 during the last trading session, reaching $1.8. About 95,574 shares traded. Cancer Genetics, Inc. (NASDAQ:CGIX) has risen 81.82% since March 16, 2017 and is uptrending. It has outperformed by 65.12% the S&P500.

Cancer Genetics, Inc. (NASDAQ:CGIX) Ratings Coverage

Among 7 analysts covering Cancer Genetics (NASDAQ:CGIX), 6 have Buy rating, 0 Sell and 1 Hold. Therefore 86% are positive. Cancer Genetics has $8 highest and $6.0 lowest target. $6.40’s average target is 255.56% above currents $1.8 stock price. Cancer Genetics had 11 analyst reports since March 11, 2016 according to SRatingsIntel. H.C. Wainwright maintained the shares of CGIX in report on Tuesday, January 16 with “Buy” rating. The firm has “Buy” rating by Aegis Capital given on Tuesday, March 15. The stock of Cancer Genetics, Inc. (NASDAQ:CGIX) has “Buy” rating given on Thursday, September 21 by H.C. Wainwright. The firm has “Buy” rating by Rodman & Renshaw given on Monday, September 26. The firm earned “Buy” rating on Wednesday, November 29 by H.C. Wainwright. The stock of Cancer Genetics, Inc. (NASDAQ:CGIX) has “Buy” rating given on Tuesday, February 6 by H.C. Wainwright. H.C. Wainwright maintained Cancer Genetics, Inc. (NASDAQ:CGIX) on Tuesday, August 15 with “Buy” rating. The stock of Cancer Genetics, Inc. (NASDAQ:CGIX) earned “Neutral” rating by Janney Capital on Friday, March 11. Maxim Group initiated the shares of CGIX in report on Thursday, December 7 with “Buy” rating.

Cancer Genetics, Inc. develops, commercializes, and provides molecular and biomarker tests and services in the United States, India, and China. The company has market cap of $43.66 million. The Company’s tests enable physicians to personalize the clinical management of each individual patient by providing genomic information to diagnose, monitor, and inform cancer treatment; and enable biotech and pharmaceutical companies involved in oncology trials to select candidate populations and reduce adverse drug reactions by providing information regarding genomic factors influencing subject responses to therapeutics. It currently has negative earnings. The company's clinical services provide information on diagnosis, prognosis, and predicting treatment outcomes of cancers to guide patient management.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.